Compare Ferrari NV (RACE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ferrari NV vs Recursion Pharmaceuticals Inc — how do they compare? Ferrari NV trades at $403.79 (market cap $71.13B), while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: Ferrari NV is far larger — about 38.2× Recursion Pharmaceuticals Inc's market cap, and Ferrari NV pays a 1.04% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RACE | RXRX | |
|---|---|---|
Market Cap | $71.13B | $1.86B |
Sector | Consumer Cyclical | Health |
52-Week High | $504.09 | $6.79 |
52-Week Low | $314.63 | $2.84 |
Enterprise Value | $73.08B | $1.38B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ferrari (RACE) trades at $405.94, down 0.98% on the day, with technical indicators showing a bearish trend while fundamentals remain strong. The company reported solid Q2 2026 earnings of $2.99 EPS, beating estimates, and maintains robust profitability with 22.25% net margins. Recent news highlights Ferrari's first electric vehicle selling for $40 million at auction, demonstrating brand strength. Analyst consensus remains bullish with a $462.67 price target representing 14% upside potential from current levels.
Ferrari presents a compelling growth story with premium valuation justified by strong fundamentals, though elevated multiples leave little room for execution missteps. Key risks include luxury market cyclicality and electric vehicle transition challenges, while institutional buying activity supports long-term confidence. The stock's current technical weakness may present entry opportunities for investors believing in the company's brand power and margin stability.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ferrari NV
Ferrari engineers and manufactures some of the world's most expensive exotic sports cars. The Ferrari brand is synonymous with Formula One racing, exclusivity, Italian design, and state-of-the-art technology. Ferrari also has a captive finance company that provides funding for dealers and clients.
Read more on RACE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
